KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$187.5 million.

  • Novavax's Consolidated Net Income fell 66.84% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 219.97%. This contributed to the annual value of -$187.5 million for FY2024, which is 65.60% up from last year.
  • Per Novavax's latest filing, its Consolidated Net Income stood at -$187.5 million for FY2024, which was up 65.60% from -$545.1 million recorded in FY2023.
  • In the past 5 years, Novavax's Consolidated Net Income registered a high of -$187.5 million during FY2024, and its lowest value of -$1.7 billion during FY2021.
  • Over the past 3 years, Novavax's median Consolidated Net Income value was -$545.1 million (recorded in 2023), while the average stood at -$463.5 million.
  • As far as peak fluctuations go, Novavax's Consolidated Net Income plummeted by 316.91% in 2021, and later spiked by 65.60% in 2024.
  • Over the past 5 years, Novavax's Consolidated Net Income (Yearly) stood at -$418.3 million in 2020, then crashed by 316.91% to -$1.7 billion in 2021, then surged by 62.27% to -$657.9 million in 2022, then climbed by 17.16% to -$545.1 million in 2023, then soared by 65.60% to -$187.5 million in 2024.